| Hassan R Abul-khoudoud, MD | |
|
2201 Lexington Ave, Ashland, KY 41101-2843 | |
| (606) 408-4000 | |
| (606) 408-6825 |
| Full Name | Hassan R Abul-khoudoud |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 33 Years |
| Location | 2201 Lexington Ave, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033255112 | NPI | - | NPPES |
| 7100126920 | Medicaid | KY | |
| 3073365 | Medicaid | OH | |
| 3810018258 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 8187 (North Dakota) | Secondary |
| 207Q00000X | Family Medicine | 35.099715 (Ohio) | Secondary |
| 207Q00000X | Family Medicine | 43760 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Kings Daughters Medical Center Ohio | Portsmouth, OH | Hospital |
| Southern Ohio Medical Center | Portsmouth, OH | Hospital |
| Highlands Arh Regional Medical Center | Prestonsburg, KY | Hospital |
| Three Rivers Medical Center | Louisa, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
News Archive
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.
Genetics researchers have identified two novel gene locations that raise the risk of type 1 diabetes. As they continue to reveal pieces of the complicated genetic puzzle for this disease, the researchers expect to improve predictive tests and devise preventive strategies.
"This January marks the first anniversary of the London Declaration on Neglected Tropical Diseases - a coordinated effort by endemic countries, non-governmental organizations, drug companies, and donors to improve the lives of more than a billion of the world's poorest people by the end of the decade," a Lancet editorial writes.
A recent study demonstrated that two commercially available surface disinfectant formulations and one hand disinfection formulation that claim "virucidal activity against enveloped viruses" are effective in inactivating the SARS-CoV-2 virus. Their study has been published on the preprint server bioRxiv.
› Verified 9 days ago
| Entity Name | Ashland Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659328250 PECOS PAC ID: 7719882521 Enrollment ID: O20031204000877 |
News Archive
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.
Genetics researchers have identified two novel gene locations that raise the risk of type 1 diabetes. As they continue to reveal pieces of the complicated genetic puzzle for this disease, the researchers expect to improve predictive tests and devise preventive strategies.
"This January marks the first anniversary of the London Declaration on Neglected Tropical Diseases - a coordinated effort by endemic countries, non-governmental organizations, drug companies, and donors to improve the lives of more than a billion of the world's poorest people by the end of the decade," a Lancet editorial writes.
A recent study demonstrated that two commercially available surface disinfectant formulations and one hand disinfection formulation that claim "virucidal activity against enveloped viruses" are effective in inactivating the SARS-CoV-2 virus. Their study has been published on the preprint server bioRxiv.
› Verified 9 days ago
| Entity Name | Apogee Medical Group Kentucky Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356503114 PECOS PAC ID: 8820164411 Enrollment ID: O20080905000019 |
News Archive
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.
Genetics researchers have identified two novel gene locations that raise the risk of type 1 diabetes. As they continue to reveal pieces of the complicated genetic puzzle for this disease, the researchers expect to improve predictive tests and devise preventive strategies.
"This January marks the first anniversary of the London Declaration on Neglected Tropical Diseases - a coordinated effort by endemic countries, non-governmental organizations, drug companies, and donors to improve the lives of more than a billion of the world's poorest people by the end of the decade," a Lancet editorial writes.
A recent study demonstrated that two commercially available surface disinfectant formulations and one hand disinfection formulation that claim "virucidal activity against enveloped viruses" are effective in inactivating the SARS-CoV-2 virus. Their study has been published on the preprint server bioRxiv.
› Verified 9 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710215736 PECOS PAC ID: 6103968029 Enrollment ID: O20100217000538 |
News Archive
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.
Genetics researchers have identified two novel gene locations that raise the risk of type 1 diabetes. As they continue to reveal pieces of the complicated genetic puzzle for this disease, the researchers expect to improve predictive tests and devise preventive strategies.
"This January marks the first anniversary of the London Declaration on Neglected Tropical Diseases - a coordinated effort by endemic countries, non-governmental organizations, drug companies, and donors to improve the lives of more than a billion of the world's poorest people by the end of the decade," a Lancet editorial writes.
A recent study demonstrated that two commercially available surface disinfectant formulations and one hand disinfection formulation that claim "virucidal activity against enveloped viruses" are effective in inactivating the SARS-CoV-2 virus. Their study has been published on the preprint server bioRxiv.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hassan R Abul-khoudoud, MD Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 408-6200 | Hassan R Abul-khoudoud, MD 2201 Lexington Ave, Ashland, KY 41101-2843 Ph: (606) 408-4000 |
News Archive
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.
Genetics researchers have identified two novel gene locations that raise the risk of type 1 diabetes. As they continue to reveal pieces of the complicated genetic puzzle for this disease, the researchers expect to improve predictive tests and devise preventive strategies.
"This January marks the first anniversary of the London Declaration on Neglected Tropical Diseases - a coordinated effort by endemic countries, non-governmental organizations, drug companies, and donors to improve the lives of more than a billion of the world's poorest people by the end of the decade," a Lancet editorial writes.
A recent study demonstrated that two commercially available surface disinfectant formulations and one hand disinfection formulation that claim "virucidal activity against enveloped viruses" are effective in inactivating the SARS-CoV-2 virus. Their study has been published on the preprint server bioRxiv.
› Verified 9 days ago
Larry S. Fields, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1101 Saint Christopher Dr, Suite 250, Ashland, KY 41101 Phone: 606-836-3196 Fax: 606-836-2564 | |
Dr. Chad Andrew Mccreary, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 Fax: 606-408-6825 | |
Robert Howard Atkins, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 Fax: 606-408-6825 | |
Mittra Esmaeili, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 398 Diederich Blvd, Ashland, KY 41101 Phone: 606-324-8060 Fax: 606-325-6889 | |
Michael Basedow, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Ashland Dr Ste 303, Ashland, KY 41101 Phone: 606-467-2360 Fax: 606-467-2359 | |
Kristie Dickess, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1480 Carter Ave, Ashland, KY 41101 Phone: 606-329-1890 |